

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 067 191 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
10.01.2001 Bulletin 2001/02

(51) Int. Cl. 7: **C12N 15/60, C12N 9/88,
C12P 13/06**

(21) Application number: 00114458.3

(22) Date of filing: 05.07.2000

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 09.07.1999 RU 99114325

(71) Applicant: Ajinomoto Co., Ltd.
Tokyo (JP)

(72) Inventors:

- Gussyatiner, Mikhail Markovich
Moscow 113535 (RU)

• Lunts, Maria Grigorievna

Moscow 121096 (RU)

• Kozlov, Yury Ivanovich

Moscow 117574 (RU)

• Ivanovskaya, Lirina Valerievna

Moscow 113525 (RU)

• Voroshilova, Elvira Borisovna

Moscow 113535 (RU)

(74) Representative:

Strehl Schübel-Hopf & Partner

Maximilianstrasse 54

80538 München (DE)

(54) **DNA coding for mutant isopropylmalate synthase, L-leucine-producing microorganism and method for producing L-leucine**

(57) A method for producing L-leucine, comprising the steps of: culturing a bacterium which is transformed with a DNA coding for an α -isopropylmalate synthase desensitized in feedback inhibition by L-leucine, in a culture medium to produce and accumulate L-leucine in the medium, and recovering L-leucine from the medium.

EP 1 067 191 A2

Description

BACKGROUND OF THE INVENTION

[0001] The present invention relates to DNA coding for a mutant α -isopropylmalate synthase. Also, the present invention relates to an L-leucine-producing microorganism having the mutant α -isopropylmalate synthase, and a method for producing L-leucine by using the microorganism. L-Leucine is an essential amino acid which can be used as a nutritious additive for food or feed, reagents or materials for medical treatment, pharmaceutical or chemical industry, or a growth factor used for production of other amino acids such as lysine.

[0002] In the past, L-leucine have been produced by a method of fermentation primarily using microorganisms belonging to the genus *Brevibacterium*, *Corynebacterium* or *Serratia* or mutants thereof which produce L-leucine (Amino acid fermentation, JAPAN SCIENTIFIC SOCIETY'S PRESS, pp.397-422, 1986).

[0003] The highest level of L-leucine accumulation was obtained when using *Brevibacterium flavum* VKPM B-2736: this strain produces L-leucine at a concentration up to 26 g/L on sucrose-containing media for 72 h of fermentation in a laboratory fermenter (USSR Author Certificate 1394711). And *Brevibacterium lactofermentum* 34 produces L-leucine up to 34 g/L on a medium with glucose (Appl. Environ. Microbiol., 51, p.1024 (1986)).

[0004] As described above, the productivity of L-leucine has been improved to some extent; however, the development of a more efficient and cost-effective method for producing L-leucine is required in order to meet increasing demand for L-leucine in the future.

[0005] On the other hand, microorganisms belonging to the genus *Escherichia* is potentially utilized as a potent L-leucine-producing bacteria due to its rapid growth rate, prominent data obtained from genetic analysis and plentiful genetic materials. However, there are few reports which disclose the production of L-leucine using bacteria belonging to the genus *Escherichia*.

[0006] As L-leucine-producing bacterial strains of the genus *Escherichia*, a strain which is resistant to β -thienylalanine, a strain which is resistant to β -thienylalanine and β -hydroxyisoleucine (Japanese Patent Publication No. 62-34397 (1987) for the above) and a strain which is resistant to 4-azaleucine or 5,5,5-trifluoroisoleucine (Japanese Patent Application Laid-Open No. 8-70879 (1996)) are known.

[0007] However, there has been known neither L-leucine-resistant bacteria belonging to the genus *Escherichia* nor a relation between L-leucine resistance and a productivity of L-leucine.

SUMMARY OF THE INVENTION

[0008] The present invention has been made from the aforementioned viewpoint, an object of which is to improve a productivity of L-leucine of bacterium belonging to the genus *Escherichia* and to provide an efficient and cost-effective method for producing L-leucine.

[0009] As a result of diligent investigation in order to achieve the aforementioned object, the present inventors have found that desensitization of feedback inhibition by L-leucine of α -isopropylmalate synthase (hereinafter abbreviated as IPMS) contributes to the productivity of L-leucine, and completed the present invention.

[0010] The present invention provides a polypeptide being a variant of the amino acid sequence shown in SEQ ID NO: 2, said variant having an α -isopropylmalate synthase activity and showing decreased feedback inhibition of the activity by L-leucine. That is, the degree of feedback inhibition of the variant is lower than the degree of feedback inhibition of the polypeptide shown in SEQ ID NO: 2, i.e. a wild type polypeptide derived from a microorganism of the genus *Escherichia*.

[0011] The polypeptide of the present invention preferably allows the production of L-leucine in a microorganism containing said polypeptide. This means that the presence of said polypeptide in a microorganism, that is no producer of L-leucine, renders this microorganism a producer of L-leucine. Furthermore, the presence of the polypeptide of the invention in an L-leucine producing microorganism increases the productivity of L-leucine of said microorganism. In a preferred embodiment of the present invention, the polypeptide allows the production of at least 0.3 g/l of L-leucine after 48 hours of cultivation at 32 °C in a microorganism that does not produce L-leucine when it does not contain said polypeptide.

[0012] The polypeptide of the present invention preferably shows such a degree of feedback inhibition that the leucine concentration causing 50 % inhibition (I_{50}) of the α -isopropylmalate synthase activity is at least 7 times the concentration of leucine causing 50 % inhibition of the wild type polypeptide. In an embodiment of the present invention, the I_{50} value is higher than 0.2 mM, preferably at least 1.4 mM.

[0013] The specific activity of the polypeptide of the present invention is preferably equal to or higher than the specific activity of the wild type polypeptide. The specific activity is preferably at least 9 nmol/(min x ng protein). The variations in the polypeptide of the present invention comprise a substitution, deletion, insertion and/or addition of one or more amino acid residue(s) compared to the polypeptide shown in SEQ ID NO: 2.

[0014] The present invention provides a protein of the following (A) or (B) and a DNA coding for said protein (hereinafter also referred to as DNA of the present invention):

(A) a protein having an amino acid sequence shown in SEQ ID NO: 2 which has a substitution selected from the following (a) to (e):

- (a) a substitution of another amino acid residue for a threonine residue at position 482,
- (b) a substitution of another amino acid residue for a glutamic acid residue at position 386,
- (c) a substitution of another amino acid residue for a proline residue at position 428,
- (d) a substitution of another amino acid residue for a glycine residue at position 479, and
- (e) a substitution of another amino acid residue for a glycine residue at position 462,

(B) a protein having the amino acid sequence of the protein of (A), which sequence has deletion, substitution, insertion or addition of one or a few amino acid residues. It is preferred that said protein of

(B) has a feedback inhibition of the activity by L-leucine being desensitized equivalently to that of the protein of (A), i.e. that the variations of (B) do not essentially affect the degree of feedback inhibition of the protein of (A).

[0015] The DNA of the present invention is preferably one in which the substitution is a substitution selected from the following (a') to (e'):

- (a') a substitution of an isoleucine residue for a threonine residue at position 482,
- (b') a substitution of a lysine residue for a glutamic acid residue at position 386,
- (c') a substitution of a leucine residue for a proline residue at position 428,
- (d') a substitution of a cysteine residue for a glycine residue at position 479, and
- (e') a substitution of an aspartic acid residue for a glycine residue at position 462.

[0016] Specific examples of the DNA of the present invention include ones which has a nucleotide sequence shown in SEQ ID NO: 1, which sequence has a mutation selected from the following (i) to (v):

- (i) a mutation of cytosine at position 1445 to thymine,
- (ii) a mutation of guanine at position 1156 to adenine,
- (iii) a mutation of cytosine at position 1283 to thymine,
- (iv) a mutation of guanine at position 1435 to thymine, and
- (v) a mutation of guanine at position 1385 to adenine.

[0017] The present invention also provides a microorganism which is transformed with the DNA of the present invention, and has an ability to produce L-leucine (hereinafter, also referred to as "microorganism of the present invention"). The microorganism of the present invention preferably belongs to the genus *Escherichia*. The microorganism of the present invention is more preferably *Escherichia coli*.

[0018] The present invention further provides a method for producing L-leucine, comprising the steps of:

culturing the bacterium of the present invention in a culture medium to produce and accumulate L-leucine in the medium, and
recovering L-leucine from the medium.

DETAILED DESCRIPTION OF THE INVENTION

[0019] The present invention will be explained in detail below.

(1) DNA of the present invention

[0020] The DNA of the present invention has a mutation to desensitize feedback inhibition by L-leucine of IPMS encoded by the DNA, in a DNA coding for a wild type IPMS.

[0021] The phrase "feedback inhibition by L-leucine is desensitized" means that the degree of the feedback inhibition is lowered. The lowering of the degree of feedback inhibition can be determined by measuring lowering of the IPMS activity by L-leucine and comparing it with that of a wild strain or a parent strain.

[0022] IPMS is exemplified by those originating from bacteria belonging to the genus *Escherichia*, especially IPMS originating from *E. coli*. The mutation of IPMS to desensitize feedback inhibition by L-leucine is exemplified by the fol-

lowing substitutions (a) to (e) in the amino acid sequence shown SEQ ID NO: 2:

- (a) a substitution of another amino acid residue for a threonine residue at position 482,
- (b) a substitution of another amino acid residue for a glutamic acid residue at position 386,
- (c) a substitution of another amino acid residue for a proline residue at position 428,
- (d) a substitution of another amino acid residue for a glycine residue at position 479, and
- (e) a substitution of another amino acid residue for a glycine residue at position 462.

[0023] The substitutions preferably are the following (a') to (e'):

- (a') a substitution of an isoleucine residue for a threonine residue at position 482,
- (b') a substitution of a lysine residue for a glutamic acid residue at position 386,
- (c') a substitution of a leucine residue for a proline residue at position 428,
- (d') a substitution of a cysteine residue for a glycine residue at position 479, and
- (e') a substitution of an aspartic acid residue for a glycine residue at position 462.

[0024] The DNA coding for the wild type IPMS is exemplified by one coding for IPMS originating from a bacterium belonging to the genus *Escherichia*. It is specifically exemplified by a DNA coding for an amino acid sequence shown in SEQ ID NO: 2, and is further specifically exemplified by a nucleotide sequence shown in SEQ ID NO: 1. In these sequences, those having the mutation in nucleotide sequence to cause the substitutions of amino acid residues described above are included in the DNA of the present invention. Any codon corresponding to the substituted amino acid residue is available irrelevantly to its kind, provided that it codes for the identical amino acid residue.

[0025] Specific examples of the DNA of the present invention include ones which has a nucleotide sequence shown in SEQ ID NO: 1, which sequence has a mutation selected from the following (i) to (v):

- (i) a mutation of cytosine at position 1445 to thymine,
- (ii) a mutation of guanine at position 1156 to adenine,
- (iii) a mutation of cytosine at position 1283 to thymine,
- (iv) a mutation of guanine at position 1435 to thymine, and
- (v) a mutation of guanine at position 1385 to adenine.

[0026] Further, it is postulated that a possessed IPMS is slightly different in sequence depending on difference in bacterial species and bacterial strain, however, DNAs coding for those having replacement, deletion or insertion of amino acid residue(s) at position(s) irrelevant to the enzyme activity are also included in DNA of the present invention.

In other words, a DNA coding for a protein having the amino acid sequence of the mutant IPMS, which sequence has deletion, substitution, insertion or addition of one or a few amino acid residues, said protein having an IPMS activity and feedback inhibition of the activity by L-leucine being desensitized equivalently to that of the mutant IPMS, is also included in the DNA of the present invention. Such the DNA includes those having mutations which may naturally occur such as mutations based on differences between individuals, species and genera of microorganisms having IPMS (mutants or variants).

[0027] A method for obtaining a DNA coding for the mutant IPMS is as follows.

(1) Preparation of wild type IPMS gene

[0028] A donor microorganism for the DNA containing the wild type IPMS gene or the IPMS gene having another mutation described above, is preferably exemplified by a microorganism belonging to the genus *Escherichia*. Specifically, it is possible to utilize those described in a book written by Neidhardt et al. (Neidhardt, F. C. et al., *Escherichia coli* and *Salmonella Typhimurium*, American Society for Microbiology, Washington D. C., 1208, table 1). For example, *E. coli* strains K-12, JM109, and MC1061 are exemplified. When a wild strain is used as a donor microorganism for a DNA containing a IPMS gene, a DNA containing a wild type IPMS gene can be obtained.

[0029] An example of preparation of a DNA containing a IPMS gene will be described below. At first, *E. coli* having wild type IPMS gene, for example, strain K-12, is cultivated to obtain a culture. When the microorganism described above is cultivated, cultivation may be performed in accordance with an ordinary solid culture method, however, cultivation is preferably performed by adopting a liquid culture method considering efficiency during collection of the bacterium. A medium may be used in which one or more nitrogen sources such as yeast extract, peptone, meat extract, corn steep liquor and exudate of soybean or wheat are added with one or more inorganic salts such as potassium dihydrogenphosphate, dipotassium hydrogenphosphate, magnesium sulfate, sodium chloride, magnesium chloride, ferric chloride, ferric sulfate or manganese sulfate, and further optionally and adequately added with sugar materials, vitamins

and the like. It is appropriate that the initial pH of the medium is adjusted to 6 to 8. The cultivation is performed for 4 to 24 hours at 30 to 42°C, preferably at about 37°C by means of deep culture with aeration and agitation, shaking culture or stationary culture or the like.

[0030] The culture thus obtained is centrifuged, for example, at 3,000 r.p.m. for 5 minutes to obtain a cell pellet of *E. coli* strain K-12. Chromosomal DNA can be obtained from the cell pellet by means of, for example, a method of Saito and Miura (Biochem. Biophys. Acta., 72, 619 (1963)), or a method of K. S. Kirby (Biochem. J., 64, 405 (1956)).

[0031] In order to isolate the IPMS gene from the chromosomal DNA thus obtained, a chromosomal DNA library is prepared. At first, the chromosomal DNA is partially digested with a suitable restriction enzyme to obtain a mixture of various fragments. A wide variety of restriction enzymes can be used if the degree of cutting is controlled by the cutting reaction time and the like. For example, *Sau3A*I is allowed to react on the chromosomal DNA at a temperature not less than 30°C, preferably at 37°C at an enzyme concentration of 1 to 10 units/ml for various periods of time (1 minute to 2 hours) to digest it.

[0032] Next, obtained DNA fragments are ligated with a vector DNA autonomously replicable in cells of bacteria belonging to the genus *Escherichia* to prepare recombinant DNA. Specifically, a restriction enzyme *Sau3A*I used to cut the chromosomal DNA, for example, *Bam*HI, is allowed to act on the vector DNA under a condition of a temperature not less than 30°C and an enzyme concentration of 1 to 100 units/ml for not less than 1 hour, preferably for 1 to 3 hours to completely digest it, and cut and cleave it. Next, the chromosomal DNA fragment mixture obtained as described above is mixed with the cleaved and cut vector DNA, on which DNA ligase, preferably T4 DNA ligase is allowed to act under a condition of a temperature of 4 to 16°C at an enzyme concentration of 1 to 100 units/ml for not less than 1 hour, preferably for 4 to 24 hours to obtain recombinant DNA.

[0033] The obtained recombinant DNA is used to transform a microorganism belonging to the genus *Escherichia*, for example, a IPMS deficient mutant strain such as an *Escherichia coli* strain K-12, preferably a strain JE7627 (*ponB704*; *dacB12*; *piv*⁺; *tonA2*; *dapA*; *lysA*; *str*; *malA38*; *metB1*; *ilvH611*; *leuA371*; *proA3*; *lac-3*; *tsx-76*) to prepare a chromosomal DNA library. The transformation can be performed, for example, by a method of D. M. Morrison (Methods in Enzymology 68, 326 (1979)) or a method in which recipient bacterial cells are treated with calcium chloride to increase permeability of DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)). The strain JE7627 is available from National Institute of Genetics (Mishima-shi, Shizuoka-ken, Japan).

[0034] A bacterial strain having recombinant DNA of the IPMS gene is obtained from strains having increased IPMS activity or strains in which auxotrophy resulting from deficiency in the IPMS gene is complemented, among the obtained chromosomal DNA library. For example, a IPMS-deficient mutant strain requires L-leucine. Thus when the IPMS-deficient mutant strain is used as a host, a DNA fragment containing the IPMS gene can be obtained by isolating a bacterial strain which becomes capable of growing on a medium containing no L-leucine, and recovering recombinant DNA from the bacterial strain.

[0035] Confirmation of the fact whether or not a candidate strain having recombinant DNA containing a IPMS gene actually harbors recombinant DNA in which the IPMS gene is cloned can be achieved by preparing a cellular extract from the candidate strain, and preparing a crude enzyme solution therefrom to confirm whether or not the IPMS activity has been increased. A procedure to measure the enzyme activity of IPMS can be performed by a method of Kohlhaw et al. (J. Biol. Chem., 244, 2218(1969)).

[0036] Recombinant DNA in which the DNA containing the IPMS gene is inserted into the vector DNA can be isolated from the bacterial strain described above by means of, for example, a method of P. Guerry et al. (J. Bacteriol., 116, 1064 (1973)) or a method of D. B. Clewell (J. Bacteriol., 110, 667 (1972)).

[0037] Preparation of the wild type IPMS gene can be also performed by preparing chromosomal DNA from a strain having a IPMS gene on chromosome by means of a method of Saito and Miura or the like, and amplifying the IPMS gene by means of a polymerase chain reaction (PCR) method (see White, T. J. et al.; Trends Genet., 5, 185 (1989)). DNA primers to be used for the amplification reaction are those complementary to both 3'-terminals of a double stranded DNA containing an entire region or a partial region of the IPMS gene. When only a partial region of the IPMS gene is amplified, it is necessary to use such DNA fragments as primers to perform screening of a DNA fragment containing the entire region from a chromosomal DNA library. When the entire region of the IPMS gene is amplified, a PCR reaction solution including DNA fragments containing the amplified IPMS gene is subjected to agarose gel electrophoresis, and then an aimed DNA fragment is extracted. Thus a DNA fragment containing the IPMS gene can be recovered.

[0038] The DNA primers may be adequately prepared on the basis of, for example, a sequence known in *E. coli* (EMBL accession No. D10483 or AE000117). Specifically, primers which can amplify a region comprising 1572 nucleotides coding for the IPMS gene are preferable. Synthesis of the primers can be performed by an ordinary method such as a phosphoramidite method (see Tetrahedron Letters, 22, 1859 (1981)) by using a commercially available DNA synthesizer (for example, DNA Synthesizer Model 380B produced by Applied Biosystems). Further, the PCR can be performed by using a commercially available PCR apparatus (for example, DNA Thermal Cycler Model PJ2000 produced by Takara Shuzo Co., Ltd.), using Taq DNA polymerase (supplied by Takara Shuzo Co., Ltd.) in accordance with a

method designated by the supplier.

[0039] With respect to the IPMS gene amplified by the PCR method, operations such as introduction of mutation into the IPMS gene become easy, when it is ligated with a vector DNA autonomously replicable in cells of bacteria belonging to the genus *Escherichia*, and introduced into cells of bacteria belonging to the genus *Escherichia*. The vector DNA to be used, the transformation method, and the confirmation method for the presence of the IPMS gene are the same as those in the aforementioned procedure.

[0040] Reports on isolation of the IPMS gene include Hertberg, K.M. et al., Gene, 8, 135-152(1980), Davis, M.G. et al., J. Bacteriol., 129, 1078-1090(1977) and the like.

[0041] The method for obtaining the IPMS gene as mentioned above may be used for obtaining mutant genes when a microorganism having a wild type IPMS is subjected to mutagenesis to produce a mutant strain producing a mutant IPMS and a mutant gene is obtained from the mutant strain.

(2) Introduction of mutation into IPMS gene

[0042] The method for carrying out mutation such as substitution, insertion and deletion of amino acid residues is exemplified by a recombinant PCR method (Higuchi, R., 61, in PCR Technology (Erich, H. A. Eds., Stockton press (1989))), and a site specific mutagenesis method (Kramer, W. and Frits, H. J., Meth. in Enzymol., 154, 350 (1987); Kunkel T. A. et al., Meth. in Enzymol., 154, 367 (1987)). Aimed mutation can be caused at an aimed site by using these methods.

[0043] Further, according to chemical synthesis of an aimed gene, it is possible to introduce mutation or random mutation into an aimed site.

[0044] Further, a method is available in which the IPMS gene on chromosome or plasmid is directly treated with hydroxylamine (Hashimoto, T. and Sekiguchi, M. J. Bacteriol., 159, 1039 (1984)). Alternatively, it is acceptable to use a method in which a bacterium belonging to the genus *Escherichia* having the IPMS gene is irradiated by ultraviolet light, or a method based on a treatment with a chemical agent such as N-methyl-N'-nitrosoguanidine or nitrous acid. According to these methods, mutation can be introduced randomly.

[0045] With respect to a selection method for the mutant gene, recombinant DNA comprising a DNA fragment containing the IPMS gene and vector DNA is at first directly subjected to a mutation treatment with hydroxylamine or the like, which is used to transform, for example, an *E. coli* strain W3110. Next, transformed strains are cultivated on a minimal medium such as M9 containing 4-aza-D,L-leucine or 3-hydroxy-D,L-leucine as an analog of L-leucine. Strains harboring recombinant DNA containing the wild type IPMS gene cannot synthesize L-leucine and are suppressed in growth because IPMS expressed from the recombinant DNA is inhibited by the analog of L-leucine. On the contrary, a strain harboring recombinant DNA containing the IPMS gene in which inhibition by L-leucine is desensitized has a mutant enzyme encoded by the IPMS gene in the aforementioned recombinant DNA which is not inhibited by the analog of L-leucine. Thus it should be capable of growth on the minimal medium in which the analog of L-leucine is added. This phenomenon can be utilized to select a strain which is resistant in growth to the analog of L-leucine, that is a strain harboring recombinant DNA containing a mutant IPMS gene in which inhibition is desensitized.

[0046] The mutant gene thus obtained may be introduced as a recombinant DNA into a suitable host microorganism, and expressed. Thus a microorganism can be obtained which harbors IPMS being desensitized to feedback inhibition. The host is preferably a microorganism belonging to the genus *Escherichia*, for which *E. coli* is exemplified.

[0047] Alternatively, a mutant IPMS gene fragment may be taken out from the recombinant DNA, and inserted into another vector to make use. The vector DNA which can be used in the present invention is preferably plasmid vector DNA, for which there are exemplified pUC19, pUC18, pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219 and pMW218. Besides, vectors of phage DNA can be also utilized.

[0048] Further, in order to express the mutant IPMS gene efficiently, another promoter which works in microorganisms such as *lac*, *trp* and PL may be ligated upstream from a DNA sequence coding for the mutant IPMS, or a promoter contained in the IPMS gene may be used as it is, or after amplifying the promoter.

[0049] In addition, as described above, the mutant gene may be inserted into an autonomously replicable vector DNA, which is inserted into a host, and allowed to be harbored by the host as extrachromosomal DNA such as a plasmid. Alternatively, the mutant gene may be integrated into chromosome of a host microorganism by a method using transduction, transposon (Berg, D. E. and Berg, C. M., Bio/Technol., 1, 417 (1983)), Mu phage (Japanese Patent Laid-open No. 2-109985) or homologous recombination (Experiments in Molecular Genetics, Cold Spring Harbor Lab. (1972)).

(2) Microorganism of the present invention

[0050] The microorganism of the present invention is the microorganism which is transformed with the DNA of the present invention and has an ability to produce L-leucine.

[0051] The transformation by the DNA of the present invention may be carried out in accordance with conventional and known transformation methods. For example, a fragment including the DNA of the present invention is ligated with a vector which functions in a host (microorganism to be transformed) to prepare a recombinant DNA, and the recombinant DNA is introduced in the host. The vector may be suitably selected depending on the host. The introduction of the recombinant DNA in accordance with conventional and known methods. For example, it is possible to use a method in which recipient cells are treated with calcium chloride to increase permeability of DNA as reported for *Escherichia coli* K-12 (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)), and a method in which competent cells are prepared from cells at a proliferating stage to introduce DNA thereinto as reported for *Bacillus subtilis* (Duncan, C. H., Wilson, G. A. and Yound, F. E., Gene, 1, 153 (1977)). Alternatively, it is also possible to apply a method in which DNA recipient cells are converted into a state of protoplasts or spheroplasts which easily incorporate recombinant DNA to introduce recombinant DNA into DNA recipients as known for *Bacillus subtilis*, actinomycetes, and yeast (Chang, S and Choen, S. N., Molec. Gen. Genet., 168, 111 (1979); Bibb, M. J., Ward, J. M. and Hopwood, O. A., Nature, 274, 398 (1978); Hinnen, A., Hicks, J. B. and Fink, G. R., Proc. Natl. Acad. Sci. USA, 75, 1929 (1978)). Also, an electric pulse method (Japanese Patent Application Laid-Open No. 2-207791 (1990)) may be used. The introduction method may be suitably selected depending on the host. Specifically, the vector and the method are exemplified by those described in the above (1) (2).

[0052] The terms "having an ability to produce L-leucine" used herein means to accumulate L-leucine in a medium, preferably, in an amount such that L-leucine can be easily recovered from the medium.

[0053] The bacterium of the present invention preferably belongs to the genus *Escherichia*. It may be exemplified by *Escherichia coli*. A bacterium belonging to the genus *Escherichia* which has an ability to produce L-leucine is exemplified, for example, by bacteria having a resistance to leucine analog such as β -2-thienylalanine, 3-hydroxyleucine, 4-azaleucine and 5,5,5-trifluoroleucine, which are described in Japanese Patent Publication No. 62-34397 (1987) and Japanese Patent Application Laid-Open No. 8-70879 (1996), and by bacterium which can be bred by genetic engineering techniques as described in WO96/06926.

[0054] In a bacterium belonging to the genus *Escherichia*, L-leucine is synthesized through biosynthetic pathway inherent to L-leucine which diverges from the final intermediate (2-ketoisovalerate) of L-valine biosynthesis system. In a bacterium belonging to the genus *Escherichia*, the final step of L-valine biosynthesis and biosynthesis inherent to L-leucine are carried out by a group of enzymes encoded by *ilvGMEDA* operon and those encoded by *leuABCD* operon, respectively.

[0055] The *leuABCD* operon includes *leuA*, *leuB*, *leuC* and *leuD* genes. Among them, *leuA* encodes IPMS, *leuB* encodes β -isopropylmalate dehydrogenase, *leuC* and *leuD* encodes α -isopropylmalate isomerase. Of these enzymes, IPMS catalyzes the synthetic reaction from α -ketoisovalerate to α -isopropylmalate, α -isopropylmalate isomerase catalyzes the isomerization reaction from β -isopropylmalate to α -isopropylmalate and β -isopropylmalate dehydrogenase catalyzes the dehydrogenation reaction from β -isopropylmalate to α -ketoisocaproic acid which is the final intermediate of L-leucine biosynthesis.

[0056] Of above-mentioned reactions in the L-leucine biosynthetic pathway, the rate determining step is the synthetic reaction from α -ketoisovalerate to α -isopropylmalate catalyzed by α -isopropylmalate synthase which suffers feedback inhibition by L-leucine. Therefore, transformation with the DNA coding for IPMS desensitized in the feedback inhibition can impart the ability to produce L-leucine to a microorganism or improve the ability to produce L-leucine of a microorganism.

[0057] The bacterium belonging to the genus *Escherichia* of the present invention may be enhanced in activity of one or more enzymes of L-leucine biosynthetic pathway by usual mutation treatment or genetic engineering techniques. Such an enhancement of the activity of the enzyme may be performed by introduction of recombinant DNA which is obtained by inserting a DNA fragment having an entire or a partial *ilvGMEDA* operon and/or *leuABCD* operon into a plasmid, phage or transposon to a bacterium belonging to the genus *Escherichia*.

[0058] The analysis of the nucleotide sequence of *leuABCD* operon was described in Nucleic Acid Res., 20, 3305-3308 (1992). The entire sequence of *leuABCD* operon has been registered in the database (DDBJ accession no. D10483, internet address of DDBJ: <http://www.ddbj.nig.ac.jp>). A DNA fragment having *leuABCD* operon can be obtained by amplifying the DNA fragment in accordance with PCR (polymerase chain reaction, refer to White, T.J., et al., Trends Genet., 5, 185 (1989)) in which oligonucleotides prepared on the basis of the above described sequences are used as primers and chromosomal DNA of a bacterium belonging to the genus *Escherichia* is used as template for PCR. Alternatively, *leuABCD* operon can also be obtained by screening a chromosomal DNA library of a bacterium belonging to the genus *Escherichia* in accordance with hybridization by using an oligonucleotide probe prepared on the basis of the above described sequences.

[0059] The entire nucleotide sequence of *ilvGMEDA* operon and the nucleotide sequence of upstream region of the operon are described in Nucleic Acid Res., 15, 2137-2155 (1987) and Gene, 97, 21-27 (1991), respectively. A DNA fragment having *ilvGMEDA* operon can be obtained by PCR or hybridization using oligonucleotide probe or primers prepared on the basis of the above described sequence. Incidentally, in the case of using *Escherichia coli* K-12 or its derivative to obtain *ilvGMEDA* operon, it is preferable to use a strain having a reverse mutation of *ilvG* gene in which

the frame is restored so as to recover the activity of the acetohydroxy acid synthase. The methods for obtaining *livGMEDA* operon and the method for amplifying the operon in a cell of a bacterium belonging to the genus *Escherichia* are fully described in WO96/06926 and FR 2627508, respectively.

(3) Method for producing L-leucine

[0060] L-Leucine can be efficiently produced by cultivating the bacterium which can be obtained as described above in a culture medium, producing and accumulating L-leucine in the medium, and recovering L-leucine from the medium.

[0061] In the method of present invention, the cultivation of the bacterium belonging to the genus *Escherichia*, the collection and purification of L-leucine from the liquid medium may be performed in a manner similar to the conventional fermentation method by which L-leucine is produced using a bacterium. A medium used in culture may be either a synthetic medium or a natural medium, so long as the medium includes a carbon and a nitrogen source and minerals and, if necessary, a suitable amount of nutrients which the bacterium used requires for growth. The carbon source may include one or more of various carbohydrates such as glucose and sucrose, and various organic acids. Regarding the mode of assimilation of the used bacterium, alcohol including ethanol and glycerol may be used. As the nitrogen source, it is possible to use various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean hydrolyte or digested fermentative microbe. As minerals, potassium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, or calcium carbonate may be used.

[0062] The cultivation is performed preferably under aerobic conditions such as a shaking culture, and an aeration and stirring culture, at a temperature of 20 to 40°C, preferably between 30 and 38°C. The pH of the culture is usually between 5 and 9, preferably between 6.5 and 7.2. The pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, cultivation for 1 to 3 days leads to the accumulation of the target L-leucine in the liquid medium.

[0063] After cultivation, insoluble substances such as cells are removed from the liquid medium by centrifugation and membrane filtration, and then the target L-leucine can be collected and purified by ionexchange, concentration and precipitation.

[0064] A microorganism of the present invention can be utilized as L-leucine producing strain or starting source for breeding of L-leucine producing strain. The present invention make it possible to produces L-leucine more efficiently in comparison with a formerly known method of producing L-leucine using a microorganism.

Examples

[0065] The present invention will be more concretely explained below with reference to Examples.

Example 1: Obtaining of DNA coding for mutant IPMS

(1) Obtaining of L-leucine-producing strains

[0066] The strains of *Escherichia coli*, producing L-leucine, were obtained from the standard laboratory wild-type strain *E. coli* K-12 by selection as described below. Cells of the strain *E. coli* K-12 were treated by solution of mutagen, containing 0.2 mg/ml N-methyl-N-nitro-N-nitrosoguanidine, for 30 min at 37°C. Then the cells were washed twice with NaCl solution (0.8%) and were spread on M9 agar medium dishes, containing 1 mg/ml of analog of L-leucine, 4-azaleucine. Colonies arisen after 5 days of incubation at 37°C were picked up and the their capability of leucine production was tested. The strains No. 9, No. 68, No. 58, No. 55, and No. 15 produced L-leucine.

(2) Obtaining of *leuA* gene from L-leucine-producing strains

[0067] The *leuA* gene of the obtained leucine-producing mutant No. 55 and that of the wild-type strain *E. coli* K-12 were cloned by the in vivo cloning method using defective bacteriophage Mu d5005 (Groisman, E.A. et al., J. Bacteriol., 168, 357 (1986)). Then overlapping fragments of thus cloned *leuA* gene were amplified by means of the PCR method, using the DNA primers, LeuA1 and LeuA2, LeuA3 and LeuA4, LeuA5 and LeuA6, LeuA7 and LeuA8, and LeuA9 and LeuA10, respectively, shown in Table 1.

Table 1

Primers used for PCR		
N	Structure (5'→3')	SEQ ID NO.
LeuA1	ccaataaccgtcccccggc	3
LeuA2	ggtgaatacagcctgacc	4
LeuA3	gtgatgcggttaattgcctg	5
LeuA4	tgacctctcgttcggggcgt	6
LeuA5	gattcagctggattggttc	7
LeuA6	cgacgattgggcctggcg	8
LeuA7	ggcatgtaccgccgccagtga	9
LeuA8	gaagccttcgtattcatacc	10
LeuA9	cagcttggcggcgtatgc	11
LeuA10	gcccgaagcgaggcgctct	12

[0068] The same DNA primers were used for amplification of the *leuA* genes from the chromosomes of the strains No. 9, No. 68, No. 58, and No. 15 without preliminarily cloning. The nucleotide sequences of the fragments were determined by dideoxy chain termination method.

[0069] The *leuA* genes from the strains No. 9, No. 68, No. 58, No. 55, and No. 15 contained mutations, indicated in the Table 2.

[0070] Cells of the strains were grown for 10 hours at 32°C in the medium containing glucose (6%), ammonium sulfate (1.5%), potassium dihydrophosphate (0.2%), magnesium sulfate (0.1%), chalk (2.5%), and thiamine (0.1 mg/l). Cell-free extracts were obtained by sonication and ammonia sulfate precipitation was used as an enzyme preparation. Specific IPMS activity was determined by the method of Kohilaw et al. (J. Biol. Chem., 244, 2218 (1969)). I_{50} is a leucine concentration which causes 50% inhibition of the enzyme activity. L-Leucine production was determined after 48 hours of cultivation in the medium indicated above.

[0071] The results are summarized in Table 2.

Table 2

Properties of the L-leucine-producing mutants				
Strain	Substitution of amino acid (Substitution of nucleotide)	IPMS		Leucine production (g/l)
		Specific Activity (nmol/min/mg protein)	I_{50} (mM)	
K-12 (wild)	None (none)	9	0.2	0.0
9	Thr ₄₈₂ →Ile (C ₁₄₄₅ →T)	25	1.4	0.8
68	Glu ₃₈₆ →Lys (G ₁₁₅₆ →A)	21	1.4	2.3
58	Pro ₄₂₈ →Leu (C ₁₂₈₃ →T)	29	2.5	1.0
55	Gly ₄₇₉ →Cys (G ₁₄₃₅ →T)	10	8.2	5.2
15	Gly ₄₆₂ →Asp (G ₁₃₈₅ →A)	9	>10.0	1.0

Example 2: Production of L-leucine by transformants

[0072] *E. coli* C600 (*leu*⁻) (Appleyard R.K., Genetics, 39, 440-452 (1954)) was transduced by P1 phages grown on

EP 1 067 191 A2

leucine-producing strains No. 9, No. 68, No. 58, No. 55 and No. 15, and *E. coli* K-12. Leu⁺ transductants were obtained and tested for the ability to produce L-leucine. The data are present in Table 3.

Table 3

Production of L-leucine by transductants	
Donor strain	Leucine production* (g/l)
<i>E. coli</i> K-12	0
9	0.55
68	0.6
58	0.3
15	1.0
55	1.3

* L-Leucine production was determined after 48 hours of cultivation at 32°C. The data of production present average of 10 transductants of each type.

SEQUENCE LISTING

5 <110> Ajinomoto Co., Inc.

<120> DNA CODING FOR MUTANT ISOPROPYLMALATE SYNTHASE, L-LEUCINE-PRODUCING
MICROORGANISM AND METHOD FOR PRODUCING L-LEUCINE

10 <130> EPA-53417

15 <150> RU 99114325
<151> 1999-07-09

<160> 12

20 <210> 1
<211> 1572
<212> DNA
25 <213> Escherichia coli

<220>
<221> CDS
30 <222> (1)...(1569).

<400> 1

35 atg agc cag caa gtc att att ttc gat acc aca ttg cgc gac ggt gaa 48
Met Ser Gln Gln Val Ile Ile Phe Asp Thr Thr Leu Arg Asp Gly Glu
1 5 10 15

cag gcg tta cag gca agc ttg agt gtg aaa gaa aaa ctg caa att gcg 96
40 Gln Ala Leu Gln Ala Ser Leu Ser Val Lys Glu Lys Leu Gln Ile Ala
20 25 30

ctg gcc ctt gag cgt atg ggt gtt gac gtg atg gaa gtc ggt ttc ccc 144
45 Leu Ala Leu Glu Arg Met Gly Val Asp Val Met Glu Val Gly Phe Pro
35 40 45

gtc tct tcg ccg ggc gat ttt gaa tcg gtg caa acc atc gcc cgc cag 192
Val Ser Ser Pro Gly Asp Phe Glu Ser Val Gln Thr Ile Ala Arg Gln
50 55 60

gtt aaa aac agc cgc gta tgt gcg tta gct cgc tgc gtg gaa aaa gat 240

EP 1 067 191 A2

	Val	Lys	Asn	Ser	Arg	Val	Cys	Ala	Leu	Ala	Arg	Cys	Val	Glu	Lys	Asp	
	65					70					75					80	
5	atc	gac	gtg	gcg	gcc	gaa	tcc	ctg	aaa	gtc	gcc	gaa	gcc	ttc	cgt	att	288
	Ile	Asp	Val	Ala	Ala	Glu	Ser	Leu	Lys	Val	Ala	Glu	Ala	Phe	Arg	Ile	
				85						90					95		
	cat	acc	ttt	att	gcc	act	tcg	cca	atg	cac	atc	gcc	acc	aag	ctg	cgc	336
10	His	Thr	Phe	Ile	Ala	Thr	Ser	Pro	Met	His	Ile	Ala	Thr	Lys	Leu	Arg	
				100					105					110			
	agc	acg	ctg	gac	gag	gtg	atc	gaa	cgc	gct	atc	tat	atg	gtg	aaa	cgc	384
	Ser	Thr	Leu	Asp	Glu	Val	Ile	Glu	Arg	Ala	Ile	Tyr	Met	Val	Lys	Arg	
15				115				120					125				
	gcc	cgt	aat	tac	acc	gat	gat	gtt	gaa	ttt	tct	tgc	gaa	gat	gcc	ggg	432
	Ala	Arg	Asn	Tyr	Thr	Asp	Asp	Val	Glu	Phe	Ser	Cys	Glu	Asp	Ala	Gly	
		130				135					140						
20	cgt	aca	ccc	att	gcc	gat	ctg	gcg	cga	gtg	gtc	gaa	gcg	gcg	att	aat	480
	Arg	Thr	Pro	Ile	Ala	Asp	Leu	Ala	Arg	Val	Val	Glu	Ala	Ala	Ile	Asn	
		145			150				155					160			
	gcc	ggt	gcc	acc	acc	atc	aac	att	ccg	gac	acc	gtg	ggc	tac	acc	atg	528
25	Ala	Gly	Ala	Thr	Thr	Ile	Asn	Ile	Pro	Asp	Thr	Val	Gly	Tyr	Thr	Met	
				165				170					175				
	ccg	ttt	gag	ttc	gcc	gga	atc	atc	agc	ggc	ctg	tat	gaa	cgc	gtg	cct	576
	Pro	Phe	Glu	Phe	Ala	Gly	Ile	Ile	Ser	Gly	Leu	Tyr	Glu	Arg	Val	Pro	
30				180				185					190				
	aac	atc	gac	aaa	gcc	att	atc	tcc	gta	cat	acc	cac	gac	gat	ttg	ggc	624
	Asn	Ile	Asp	Lys	Ala	Ile	Ile	Ser	Val	His	Thr	His	Asp	Asp	Leu	Gly	
		195				200				205							
35	ctg	gcg	gtc	gga	aac	tca	ctg	gcg	gcg	gta	cat	gcc	ggt	gca	cgc	cag	672
	Leu	Ala	Val	Gly	Asn	Ser	Leu	Ala	Ala	Val	His	Ala	Gly	Ala	Arg	Gln	
		210				215				220							
	gtg	gaa	ggc	gca	atg	aac	ggg	atc	ggc	gag	cgt	gcc	gga	aac	tgt	tcc	720
40	Val	Glu	Gly	Ala	Met	Asn	Gly	Ile	Gly	Glu	Arg	Ala	Gly	Asn	Cys	Ser	
		225			230			235				240					
	ctg	gaa	gaa	gtc	atc	atg	gcg	atc	aaa	gtt	cgt	aag	gat	att	ctc	aac	768
	Leu	Glu	Glu	Val	Ile	Met	Ala	Ile	Lys	Val	Arg	Lys	Asp	Ile	Leu	Asn	
45				245				250				255					
	gtc	cac	acc	gcc	att	aat	cac	cag	gag	ata	tgg	cgc	acc	agc	cag	tta	816
	Val	His	Thr	Ala	Ile	Asn	His	Gln	Glu	Ile	Trp	Arg	Thr	Ser	Gln	Leu	
				260				265				270					
50	gtt	agc	cag	att	tgt	aat	atg	ccg	atc	ccg	gca	aac	aaa	gcc	att	gtt	864
	Val	Ser	Gln	Ile	Cys	Asn	Met	Pro	Ile	Pro	Ala	Asn	Lys	Ala	Ile	Val	
		275				280					285						

55

EP 1 067 191 A2

5 ggc agc ggc gca ttc gca cac tcc tcc ggt ata cac cag gat ggc gtg 912
 Gly Ser Gly Ala Phe Ala His Ser Ser Gly Ile His Gln Asp Gly Val
 290 295 300
 ctg aaa aac cgc gaa aac tac gaa atc atg aca cca gaa tct att ggt 960
 Leu Lys Asn Arg Glu Asn Tyr Glu Ile Met Thr Pro Glu Ser Ile Gly
 305 310 315 320
 10 ctg aac caa atc cag ctg aat ctg acc tct cgt tgc ggg cgt gcg gcg 1008
 Leu Asn Gln Ile Gln Leu Asn Leu Thr Ser Arg Ser Gly Arg Ala Ala
 325 330 335
 gtg aaa cat cgc atg gat gag atg ggg tat aaa gaa agt gaa tat aat 1056
 15 Val Lys His Arg Met Asp Glu Met Gly Tyr Lys Glu Ser Glu Tyr Asn
 340 345 350
 tta gac aat ttg tac gat gct ttc ctg aag ctg gcg gac aaa aaa ggt 1104
 Leu Asp Asn Leu Tyr Asp Ala Phe Leu Lys Leu Ala Asp Lys Lys Gly
 20 355 360 365
 cag gtg ttt gat tac gat ctg gag gcg ctg gcc ttc atc ggt aag cag 1152
 Gln Val Phe Asp Tyr Asp Leu Glu Ala Leu Ala Phe Ile Gly Lys Gln
 370 375 380
 25 caa gaa gag ccg gag cat ttc cgt ctg gat tac ttc agc gtg cag tct 1200
 Gln Glu Glu Pro Glu His Phe Arg Leu Asp Tyr Phe Ser Val Gln Ser
 385 390 395 400
 ggc tct aac gat atc gcc acc gcc gcc gtc aaa ctg gcc tgt ggc gaa 1248
 30 Gly Ser Asn Asp Ile Ala Thr Ala Ala Val Lys Leu Ala Cys Gly Glu
 405 410 415
 gaa gtc aaa gca gaa gcc gcc aac ggt aac ggt ccg gtc gat gcc gtc 1296
 Glu Val Lys Ala Glu Ala Ala Asn Gly Asn Gly Pro Val Asp Ala Val
 35 420 425 430
 tat cag gca att aac cgc atc act gaa tat aac gtc gaa ctg gtg aaa 1344
 Tyr Gln Ala Ile Asn Arg Ile Thr Glu Tyr Asn Val Glu Leu Val Lys
 435 440 445
 40 tac agc ctg acc gcc aaa ggc cac ggt aaa gat gcg ctg ggt cag gtg 1392
 Tyr Ser Leu Thr Ala Lys Gly His Gly Lys Asp Ala Leu Gly Gln Val
 450 455 460
 gat atc gtc gct aac tac aac ggt cgc cgc ttc cac ggc gtc ggc ctg 1440
 45 Asp Ile Val Ala Asn Tyr Asn Gly Arg Arg Phe His Gly Val Gly Leu
 465 470 475 480
 gct acc gat att gtc gag tca tct gcc aaa gcc atg gtg cac gtt ctg 1488
 Ala Thr Asp Ile Val Glu Ser Ser Ala Lys Ala Met Val His Val Leu
 50 485 490 495
 aac aat atc tgg cgt gcc gca gaa gtc gaa aaa gag ttg caa cgc aaa 1536
 Asn Asn Ile Trp Arg Ala Ala Glu Val Glu Lys Glu Leu Gln Arg Lys

55

EP 1 067 191 A2

500 505 510
gct caa cac aac gaa aac aac aag gaa acc gtg tga 1572
5 Ala Gln His Asn Glu Asn Asn Lys Glu Thr Val
515 520

<210> 2
10 <211> 523
<212> PRT
<213> Escherichia coli

15 <400> 2
Met Ser Gln Gln Val Ile Ile Phe Asp Thr Thr Leu Arg Asp Gly Glu
1 5 10 15
Gln Ala Leu Gln Ala Ser Leu Ser Val Lys Glu Lys Leu Gln Ile Ala
20 20 25 30
Leu Ala Leu Glu Arg Met Gly Val Asp Val Met Glu Val Gly Phe Pro
35 40 45
Val Ser Ser Pro Gly Asp Phe Glu Ser Val Gln Thr Ile Ala Arg Gln
25 50 55 60
Val Lys Asn Ser Arg Val Cys Ala Leu Ala Arg Cys Val Glu Lys Asp
65 70 75 80
Ile Asp Val Ala Ala Glu Ser Leu Lys Val Ala Glu Ala Phe Arg Ile
30 85 90 95
His Thr Phe Ile Ala Thr Ser Pro Met His Ile Ala Thr Lys Leu Arg
100 105 110
Ser Thr Leu Asp Glu Val Ile Glu Arg Ala Ile Tyr Met Val Lys Arg
35 115 120 125
Ala Arg Asn Tyr Thr Asp Asp Val Glu Phe Ser Cys Glu Asp Ala Gly
130 135 140
Arg Thr Pro Ile Ala Asp Leu Ala Arg Val Val Glu Ala Ala Ile Asn
40 145 150 155 160
Ala Gly Ala Thr Thr Ile Asn Ile Pro Asp Thr Val Gly Tyr Thr Met
165 170 175
Pro Phe Glu Phe Ala Gly Ile Ile Ser Gly Leu Tyr Glu Arg Val Pro
45 180 185 190
Asn Ile Asp Lys Ala Ile Ile Ser Val His Thr His Asp Asp Leu Gly
195 200 205
Leu Ala Val Gly Asn Ser Leu Ala Ala Val His Ala Gly Ala Arg Gln
50 210 215 220
Val Glu Gly Ala Met Asn Gly Ile Gly Glu Arg Ala Gly Asn Cys Ser
225 230 235 240

EP 1 067 191 A2

5 Leu Glu Glu Val Ile Met Ala Ile Lys Val Arg Lys Asp Ile Leu Asn
 245 250 255
 Val His Thr Ala Ile Asn His Gln Glu Ile Trp Arg Thr Ser Gln Leu
 260 265 270
 Val Ser Gln Ile Cys Asn Met Pro Ile Pro Ala Asn Lys Ala Ile Val
 275 280 285
 10 Gly Ser Gly Ala Phe Ala His Ser Ser Gly Ile His Gln Asp Gly Val
 290 295 300
 Leu Lys Asn Arg Glu Asn Tyr Glu Ile Met Thr Pro Glu Ser Ile Gly
 305 310 315 320
 15 Leu Asn Gln Ile Gln Leu Asn Leu Thr Ser Arg Ser Gly Arg Ala Ala
 325 330 335
 Val Lys His Arg Met Asp Glu Met Gly Tyr Lys Glu Ser Glu Tyr Asn
 340 345 350
 20 Leu Asp Asn Leu Tyr Asp Ala Phe Leu Lys Leu Ala Asp Lys Lys Gly
 355 360 365
 Gln Val Phe Asp Tyr Asp Leu Glu Ala Leu Ala Phe Ile Gly Lys Gln
 370 375 380
 25 Gln Glu Glu Pro Glu His Phe Arg Leu Asp Tyr Phe Ser Val Gln Ser
 385 390 395 400
 Gly Ser Asn Asp Ile Ala Thr Ala Ala Val Lys Leu Ala Cys Gly Glu
 405 410 415
 30 Glu Val Lys Ala Glu Ala Ala Asn Gly Asn Gly Pro Val Asp Ala Val
 420 425 430
 Tyr Gln Ala Ile Asn Arg Ile Thr Glu Tyr Asn Val Glu Leu Val Lys
 435 440 445
 35 Tyr Ser Leu Thr Ala Lys Gly His Gly Lys Asp Ala Leu Gly Gln Val
 450 455 460
 Asp Ile Val Ala Asn Tyr Asn Gly Arg Arg Phe His Gly Val Gly Leu
 465 470 475 480
 40 Ala Thr Asp Ile Val Glu Ser Ser Ala Lys Ala Met Val His Val Leu
 485 490 495
 Asn Asn Ile Trp Arg Ala Ala Glu Val Glu Lys Glu Leu Gln Arg Lys
 500 505 510
 45 Ala Gln His Asn Glu Asn Asn Lys Glu Thr Val
 515 520

<210> 3

50 <211> 18

<212> DNA

<213> Artificial Sequence

55

<220>

<223> Synthetic DNA

<400> 3

ccaataaccgt cccccggc

18

<210> 4

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 4

ggtgaaatac agcctgacc

19

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 5

gtgatgcggt taattgcctg

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

<400> 6

tgacctctcg ttcggggcgt

20

<210> 7

5	<211> 20 <212> DNA <213> Artificial Sequence	
10	<220> <223> Synthetic DNA	
	<400> 7 gattcagctg gatttggttc	20
15	<210> 8 <211> 19 <212> DNA <213> Artificial Sequence	
20	<220> <223> Synthetic DNA	
25	<400> 8 cgacgatttg ggcctggcg	19
30	<210> 9 <211> 21 <212> DNA <213> Artificial Sequence	
35	<220> <223> Synthetic DNA	
40	<400> 9 ggcatgtacc gccgccagtg a	21
45	<210> 10 <211> 21 <212> DNA <213> Artificial Sequence	
50	<220> <223> Synthetic DNA	
55	<400> 10	

gaagccttcc gtattcatac c

21

5

<210> 11

<211> 19

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Synthetic DNA

15

<400> 11

cagcttggtg gcgatgtgc

19

20

<210> 12

<211> 19

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Synthetic DNA

30

<400> 12

gcccgaagcg aggcgctct

19

35

Claims

- 40 1. A polypeptide being a variant of the amino acid sequence shown in SEQ ID NO: 2, said variant having an α -isopropylmalate synthase activity and showing decreased feedback inhibition of the activity by L-leucine.
2. The polypeptide according to claim 1, which allows the production of L-leucine in a microorganism containing said polypeptide.
- 45 3. The polypeptide according to claim 2, which allows the production of at least 0.3 g/l of leucine after 48 hours of cultivation at 32 °C.
- 50 4. The polypeptide according to any of the preceding claims, wherein the leucine concentration causing 50 % inhibition of the α -isopropylmalate synthase activity is at least 7 times the concentration of leucine causing 50 % inhibition of the wild type polypeptide.
- 55 5. The polypeptide according to any of the preceding claims, which has a specific activity equal to or higher than the specific activity of the wild type polypeptide.
6. The polypeptide according to any of the preceding claims, which has a specific activity of at least 9 nmol/(min x mg protein).

7. The polypeptide according to any of the preceding claims, which contains a substitution, deletion, insertion and/or addition of one or more amino acid residue(s) compared to the wild type polypeptide.
8. The polypeptide according to any of the preceding claims, wherein one or more of the following amino acid residues are substituted by another amino acid residue: threonine residue at position 482; glutamic acid residue at position 386, proline residue at position 428, glycine residue at position 479, and glycine residue at position 462.
9. The polypeptide according to claim 8, wherein the substitutions are as follows:
 - substitution of an isoleucine residue for the threonine residue at position 482;
 - substitution of a lysine residue for the glutamic acid residue at position 386;
 - substitution of a leucine residue for the proline residue at position 428;
 - substitution of a cysteine residue for the glycine residue at position 479; and
 - substitution of an aspartic acid residue for the glycine residue at position 462.
10. A DNA coding for a polypeptide according to any of the claims 1 to 9.
11. A vector containing the DNA according to claim 10.
12. A microorganism containing the DNA according to claim 10 or the vector according to claim 11.
13. A method for producing L-leucine which comprises culturing a microorganism as defined in claim 12



(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
19.03.2003 Bulletin 2003/12

(51) Int Cl.7: **C12N 15/60, C12N 9/88,
C12P 13/06**

(43) Date of publication A2:
10.01.2001 Bulletin 2001/02

(21) Application number: **00114458.3**

(22) Date of filing: **05.07.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

- **Lunts, Maria Grigorievna**
Moscow 121096 (RU)
- **Kozlov, Yury Ivanovich**
Moscow 117574 (RU)
- **Ivanovskaya, Lirina Valerievna**
Moscow 113525 (RU)
- **Voroshilova, Elvira Borisovna**
Moscow 113535 (RU)

(30) Priority: **09.07.1999 RU 99114325**

(71) Applicant: **Ajinomoto Co., Inc.**
Tokyo (JP)

(74) Representative: **Strehl Schübel-Hopf & Partner**
Maximilianstrasse 54
80538 München (DE)

(72) Inventors:
• **Gusyatiner, Mikhail Markovich**
Moscow 113535 (RU)

(54) **DNA coding for mutant isopropylmalate synthase, L-leucine-producing microorganism and method for producing L-leucine**

(57) A method for producing L-leucine, comprising the steps of: culturing a bacterium which is transformed with a DNA coding for an α -isopropylmalate synthase desensitized in feedback inhibition by L-leucine, in a cul-

ture medium to produce and accumulate L-leucine in the medium, and recovering L-leucine from the medium.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4458

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 99 28446 A (DU PONT ; ALLEN STEPHEN M (US); HITZ WILLIAM D (US); FALCO SAVERIO) 10 June 1999 (1999-06-10) * page 1, line 20 - page 3, line 20 * * examples 4,9 * * claims 31-35,56-61 * * SEQ ID NOs 16 & 17 *	1,2,8, 10-13	C12N15/60 C12N9/88 C12P13/06
X	DATABASE EMBL [Online] EMBL; 29 January 1997 (1997-01-29) BLATTNER F R ET AL.: "Escherichia coli K12 MG1655 section 7 of 400 of the complete genome" Database accession no. AE000117 XP002224768 * nucleotides 11771-13342 * * page 5, line 34-53 *	1,2,5, 10-13	
Y	US 3 970 519 A (TSUCHIDA TAKAYASU ET AL) 20 July 1976 (1976-07-20) * the whole document * * column 4, line 15-50 * * example 1 * * claims 1-3 *	1-13	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C12N C12P
Y	EP 0 913 466 A (AJINOMOTO KK) 6 May 1999 (1999-05-06) * the whole document * * column 3, line 10 - column 5, line 25 * * column 6, line 5-34 * * examples 1-3 * * claims 1-5 *	1-13	
-/--			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 December 2002	Examiner van de Kamp, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (3.92) (P4/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4458

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	AZUMA T ET AL.: "Enzymatic background for the reversion or stabilization of an L-leucine producing strain of <i>Corynebacterium glutamicum</i> " AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 52, no. 6, 1988, pages 1525-1528, XP002224765 ISSN: 0002-1369 * the whole document * * tables I,III,IV *	1-13	
Y	CAVALIERI D ET AL.: "Trifluoroleucine resistance and regulation of alpha-isopropyl malate synthase in <i>Saccharomyces cerevisiae</i> ." MOLECULAR AND GENERAL GENETICS, vol. 261, no. 1, February 1999 (1999-02), pages 152-160, XP002224766 ISSN: 0026-8925 * the whole document *	1-13	
Y	YOSHIKAWA S ET AL.: "Enhanced formation of isoamyl alcohol in <i>Zygosaccharomyces rouxii</i> due to elimination of feedback inhibition of alpha-isopropylmalate synthase." FEMS MICROBIOLOGY LETTERS, vol. 127, no. 1-2, 1995, pages 139-143, XP002224767 ISSN: 0378-1097 * the whole document *	1-13	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 December 2002	Examiner van de Kamp, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.02 (P.0401)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 11 4458

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-12-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9928446	A	10-06-1999	AU	1463299 A	16-06-1999
			AU	1539899 A	16-06-1999
			BR	9815065 A	07-11-2000
			BR	9815578 A	23-10-2001
			EP	1044264 A2	18-10-2000
			EP	1042484 A1	11-10-2000
			WO	9928446 A2	10-06-1999
			WO	9928479 A1	10-06-1999
			US	6204039 B1	20-03-2001
US 3970519	A	20-07-1976	JP	1125147 C	30-11-1982
			JP	50123877 A	29-09-1975
			JP	57009796 B	23-02-1982
			CA	1046440 A1	16-01-1979
			FR	2264088 A1	10-10-1975
			GB	1496940 A	05-01-1978
			IT	1033255 B	10-07-1979
EP 0913466	A	06-05-1999	RU	2140450 C1	27-10-1999
			EP	0913466 A2	06-05-1999
			SK	147998 A3	07-05-1999
			US	6124121 A	26-09-2000

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82